aTyr Pharma (LIFE) Stock Price, News & Analysis

Company Overview

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.57 to $2.07
• 52-Week Range: N/A
• Volume: 269,400 shs
• Average Volume: 514,103 shs
• Market Capitalization: $131.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.50
• Consensus Rating: Buy

aTyr Pharma Stock Analysis - MarketRank™

aTyr Pharma scored higher than 33% of companies evaluated by MarketBeat, and ranked 787th out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

aTyr Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

aTyr Pharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for aTyr Pharma are expected to grow in the coming year, from ($0.89) to ($0.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of aTyr Pharma is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of aTyr Pharma is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for LIFE.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

aTyr Pharma does not currently pay a dividend.

Dividend Growth

aTyr Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for LIFE.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for aTyr Pharma this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for LIFE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, aTyr Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.70% of the stock of aTyr Pharma is held by insiders.

Percentage Held by Institutions

61.72% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LIFE Stock Analysis - Frequently Asked Questions

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) released its quarterly earnings data on Thursday, May, 2nd. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.01. The biotechnology company had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.11 million.

When did aTyr Pharma's stock split?

aTyr Pharma's stock reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did aTyr Pharma IPO?

aTyr Pharma (LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that aTyr Pharma investors own include Tesla (TSLA), Plug Power (PLUG), Meta Platforms (META), NVIDIA (NVDA), SCYNEXIS (SCYX), Ford Motor (F) and NIO (NIO).

Company Calendar

• Last Earnings: 5/02/2024
• Today: 10/24/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:LIFE
• CUSIP: 53217V10
• CIK: 1339970
• Web: www.atyrpharma.com
• Phone: (858) 731-8389
• Fax: 858-731-8394
• Employees: 56
• Year Founded: 2005

Price Target and Rating

• Average Stock Price Target: $25.50
• High Stock Price Target: $35.00
• Low Stock Price Target: $16.00
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-50,390,000.00
• Net Margins: N/A
• Pretax Margin: -9,172.11%
• Return on Equity: -56.92%
• Return on Assets: -43.87%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 6.07
• Quick Ratio: 6.07

Sales & Book Value

• Annual Sales: $350,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.54 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 69,010,000
• Free Float: 66,458,000
• Market Cap: $131.12 million
• Optionable: Optionable
• Beta: 1.19